CLN3


Also found in: Acronyms, Encyclopedia, Wikipedia.

CLN3

A gene on chromosome 16p12.1 that encodes battenin, a protein involved in lysosomal function, which is defective in Batten-Spielmeyer-Vogt disease, a clinical form of neuronal ceroid lipofuscinosis.
Mentioned in ?
References in periodicals archive ?
In both assays, normal activities were found in samples from patients with CLN3, as would be expected.
Under the terms of the agreement, REGENXBIO has granted Abeona an exclusive worldwide license (subject to certain non-exclusive rights previously granted for MPS IIIA), with rights to sublicense, to REGENXBIOs NAV AAV9 vector for the development and commercialization of gene therapies for the treatment of MPS IIIA, MPS IIIB, CLN1 Disease and CLN3 Disease.
Isolation of a novel gene underlying Batten disease, CLN3. Cell 1995;82:949-57.
Under the terms of the agreement, REGENXBIO has granted Abeona an exclusive worldwide license with rights to sublicense, to REGENXBIO's NAV AAV9 vector for the development and commercialization of gene therapies for the treatment of MPS IIIA, MPS IIIB, CLN1 Disease and CLN3 Disease.
HIGH COPY SUPPRESSION ANALYSIS OF MIS-LOCALIZED G1 CYCLIN CLN3 IN THE BUDDING YEAST SACCHAROMYCES CEREVISIAE.
The neuronal ceroid lipofuscinoses (NCLs) are a group of inherited neurodegenerative diseases that include infantile NCL (INCL; OMIM 256730, where the defective gene is CLN1), classical late infantile NCL (LINCL; OMIM 204500, where the defective gene is CLN2), two variant late infantile NCLs (OMIM 256731, where the defective gene is CLN5; and OMIM 601780, where the defective gene is CLN6), juvenile NCL (JNCL; OMIM 204200; defective gene, CLN3), a juvenile onset epilepsy with progressive mental retardation (EPMR; OMIM 600143; defective gene, CLN8), and adult NCL (Kufs disease; OMIM 204300; defective gene, CLN4) [reviewed in Ref.
The lead programs in CLN6, CLN3, and CLN8 Batten disease are potential first-to-market curative therapies for these diseases.
We are excited to celebrate Abeonas first R&D day this fall and update our stakeholders on the significant progress made in our clinical stage gene therapy programs for ABO-102 and EB-101, as well as provide a review of the progress made on the IND-enabling studies for our juvenile (CLN3) and infantile (CLN1) Batten programs, stated Timothy J.
We will follow a novel integrated strategy to identify specific gene and small molecule treatments for three genetic types of Batten disease that include the most prevalent world-wide, juvenile CLN3 disease, and in southern and mediterranean Europe, CLN6 and CLN7 diseases.